Sucrase-isomaltase Deficiency as a Cause of Irritable Bowel Syndrome

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-90
SponsorLovisenberg Diakonale Hospital

About this trial

Irritable bowel syndrome (IBS) is a functional disorder causing troublesome symptoms and reduced quality of life. It affects 10-20% of the population, hence creates large costs for society. About 30-40% of all IBS patients do not benefit from current treatment options. Sucrase-isomaltase (SI) deficiency is an unexplored condition, that may explain symptoms in IBS patients who experience no effect from today's treatments. Currently, a duodenal biopsy is the gold standard for the diagnosis of SI deficiency, however the condition is not well investigated. A 13C-labelled breath test holds promise as a non-invasive alternative, but it has not previously been validated.

This project will address the knowledge gap related to a possible association between SI deficiency and IBS by addressing two research questions that have never been answered before. We aim to:

1. Validate the 13C-labelled breath test as a diagnostic tool by assessing the strength of the association between the breath test and SI activity measured in duodenal biopsies 2. Use the 13C-labelled breath test in a randomized dietary crossover trial comparing a starch and sucrose reduced diet (SSRD) with the standard low-FODMAP diet in IBS patients, to evaluate whether SI activity is associated with dietary changes according to symptom severity and gut microbiota composition

Eligibility criteria

Qualifiers

Signed informed consent

BMI 18-30 kg/m2

Referred for gastroscopic examination with suspected GI disorder

Disqualifiers

Signed informed consent

BMI 18-30 kg/m2

IBS diagnosis according to Rome IV criteria

Inflammatory bowel disease, celiac disease or diabetes mellitus

Trial design

Treatments tested in this trial

  • Low-FODMAP diet
  • Starch- and Sucrose Reduced Diet (SSRD)

Treatment groups

80 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Lovisenberg Diakonale Hospital

Lead sponsor

University of Bergen

Collaborator